163 related articles for article (PubMed ID: 37956521)
1. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Roar M; Nielsen ARH; Berg JM; Sirakov G; Stilund M; Schäfer J; Ratzer R; Frederiksen J; Asgari N; Ashna SN; Jensen HB; Kant M; Theódorsdóttir Á; Illes Z; Sellebjerg F; Magyari M; Schlosser LM; Nordborg H; Wergeland S; Sejbaek T
Mult Scler Relat Disord; 2023 Dec; 80():105127. PubMed ID: 37956521
[TBL] [Abstract][Full Text] [Related]
2. Real-life persistence and tolerability with dimethyl fumarate.
Sejbaek T; Nybo M; Petersen T; Illes Z
Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
4. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
5. Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Vural E; Engin E; Sünter G; Yıldırım KA; Günal D
Turk J Med Sci; 2023 Jun; 53(3):771-779. PubMed ID: 37476900
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
[TBL] [Abstract][Full Text] [Related]
7. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
Chu L; Balusha A; Casserly C; Berger W; Morrow SA
Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
[TBL] [Abstract][Full Text] [Related]
8. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
10. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
[TBL] [Abstract][Full Text] [Related]
11. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072
[TBL] [Abstract][Full Text] [Related]
12. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
Caldito NG; O'Leary S; Stuve O
Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
[TBL] [Abstract][Full Text] [Related]
13. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
[TBL] [Abstract][Full Text] [Related]
15. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
16. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
[TBL] [Abstract][Full Text] [Related]
17. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
19. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
